Adenomatous polyposis coli gene (APC) polymorphisms may influence the risk for colorectal neoplasia. However, results thus far have been inconclusive. We performed a systematic literature search of the Medline, Embase, Cochrane Collaboration, and HuGE databases and reviewed the references of pertinent articles through May 2012. Odds ratios with 95% confidence intervals were used to estimate the association between 3 APC polymorphisms (D1822V, E1317Q, and I1307K) and colorectal neoplasia. In total, 40 studies from 1997 to 2010 were included in this meta-analysis, and individuals with the D1822V variant homozygote VV genotype had a slight decrease in the risk for colorectal neoplasia compared with the wild-type homozygote DD genotype (pooled odds ratio = 0.87, 95% confidence interval: 0.77, 0.99). There was a small association between the APC E1317Q polymorphism and a risk for colorectal neoplasia (variant vs. wild-type: pooled odds ratio = 1.41, 95% confidence interval: 1.14, 1.76), particularly for colorectal adenomas (variant vs. wild-type: odds ratio = 2.89, 95% confidence interval: 1.83, 4.56). Compared with those who carried the wild-type I1307K, Ashkenazi Jews who carried the I1307K variant were at a significantly increased risk for colorectal neoplasia, with a pooled odds ratio of 2.17 (95% confidence interval: 1.64, 2.86). Our study suggests that APC is a candidate gene for colorectal neoplasia susceptibility.
Editor's note: This article also appears on the Web site of the Human Genome Epidemiology Network (http://www. hugenet.org.uk/index.html).
Colorectal cancer is the third most common cancer and the fourth most frequent cause of cancer death worldwide (1) . Colorectal cancer is a multifactorial disease that involves both environmental and genetic factors (2) . The adenomatous polyposis coli gene (APC) was identified in 1991, is located at 5q21-q22, and contains 15 exons; it plays a key role in the early stages of human colorectal tumorigenesis (3) . Its tumor-suppressing activity is believed to be based on the regulation of the intracellular β-catenin level within the wingless signal transduction pathway (the Wnt signaling pathway) (4) . A mutation in APC promotes the accumulation of β-catenin, which results in aberrant cellular proliferation, leading to the beginning stages of colorectal cancer (5) . APC germ-line mutations lead to the hereditary colorectal cancer syndrome, familial adenomatous polyposis (6, 7) .
Epidemiologic and biological data have suggested that within a given population, various single-nucleotide polymorphisms could be responsible for an increased risk of colorectal cancer development. Several putative low-penetrance susceptibility alleles of APC have been investigated in individuals and populations with an elevated risk of colorectal neoplasia (6) (7) (8) . The common polymorphisms in APC, which result in amino acid changes, may have functional significance, leading to dysregulation in many cancers, particularly in colorectal tumors. However, unlike the wellcharacterized pathogenic germ-line mutations in APC that are found in familial adenomatous polyposis, the consequences of common allele variants in APC as they relate to colorectal adenomas and cancer risk are less clear (9) . At least 12 single-nucleotide polymorphisms have been identified, with 8 of them being in exon 15. Three of them are responsible for amino acid substitutions (10) . D1822V, which results in an aspartate (D) to valine (V) change at codon 1822 (rs459552) due to an A-to-T transversion, is the most common APC variant that has been described (10) ; this transversion is located close to the fifth β-catenin binding region. Recently, several studies have investigated the role of D1822V polymorphisms on the risk of colorectal cancers. However, the results of these studies remain inconsistent, and no meta-analysis has been published until now.
E1317Q results in a missense glutamic acid (E) to glutamine (Q) variant at codon 1317. A meta-analysis of 8 studies of the association between E1307Q and colorectal adenoma or cancer risk was published in 2006 (11) and found no association between E1317Q and colorectal cancer ( pooled odds ratio (OR) = 1.35, 95% confidence interval (CI): 0.92, 1.97). Unfortunately, in this meta-analysis published in 2006, 3 published articles about the relationship between E1317Q and colorectal adenoma or cancer risk were not included (12) (13) (14) . Since then, 5 inconsistent studies have been published (15) (16) (17) (18) (19) . Therefore, the association between the E1317Q polymorphism and the risk of colorectal neoplasia is still unclear, and it is important to clarify this association.
The I1307K APC variant, which is an isoleucine (I) to lysine (K) substitution at codon 1307, was found in 6.1% of American Jews of European (Ashkenazi) origin and in a remarkably high proportion of Ashkenazi colorectal cancer patients (10.4%) (20) . However, the results of these studies on the prevalence of I1307K in Israeli Jews from various ethnic origins (non-Ashkenazi, such as Asia-and Africaborn Jews) and non-Jewish colorectal cancer patients and the association between I1307K and the risk for colorectal neoplasia are inconsistent and need clarification through a meta-analysis.
Both environmental and genetic factors and their interaction have been implicated in the occurrence of colorectal cancer (21) . Of the environmental factors, obesity, high fat intake, lack of physical activity, hormone replacement therapy use, and a lack of protective factors, such as dietary fruit and vegetables, have consistently been associated with a greater risk of colorectal cancer (22, 23) . In the presence of high fat intake, which is a cancer promoter, the production of diacylglycerol may increase. High concentrations of diacylglycerol promote greater activation of protein kinase C, which can activate the Wnt signaling pathway and thereby promote cancer growth (24) .
Therefore, we performed a meta-analysis that was based on published studies to comprehensively assess the association between the main APC polymorphisms and potential interactions with environmental factors and the risk for colorectal neoplasia.
MATERIALS AND METHODS

Primary search strategy
We conducted a systematic literature search in the Medline, Embase, Cochrane Collaboration, and HuGE databases through May 2012 by using the following keywords: colorectal cancer; colorectal carcinoma; colorectal neoplasia; colorectal tumor; colorectal adenoma; D1822V; I1307K; E1317Q; and polymorphism. The references in the retrieved studies were also reviewed.
Criteria for inclusion and exclusion
All published original papers were screened. Studies performed in humans, regardless of sample size, were included if they met the following criteria: 1) the study investigated the association between at least 1 of the 3 polymorphisms of APC (D1822V, E1317Q, or I1307K) and the risk of colorectal neoplasia; 2) the study reported the genotypic frequencies of the I1307K polymorphisms in unrelated colorectal neoplasia patients and unrelated individual controls; and 3) the genotype distribution of the control population was in Hardy-Weinberg equilibrium. Moreover, for articles that had the same population or repeated data, the most recent or the largest sample was included; if the population of 1 article was the same as others but the sample was not the same, then a merged sample was included.
Data extraction
Two reviewers independently searched the literature, extracted data, and conferred over any difference until a consensus was reached for each item. Information was collected from each article, including the first author, year of publication, country (and subjects' ethnicity), tumor type, selection criteria and characteristics of cases and controls, genotype frequency, matching condition, odds ratio, and corresponding 95% confidence interval.
Quality score assessment and Venice criteria
The 2 reviewers (J.L. and C.Q.L) independently assessed the quality of the studies selected by using the quality assessment score developed for genetic association studies (25) , which is based on both traditional epidemiologic considerations and genetic issues (26) . Total scores ranged from 0 (worst) to 12 (best). In this meta-analysis, we also used the "Venice criteria" to assess the cumulative evidence of the associations (27) . The evidence level is categorized as strong, moderate, or weak. Any differences were adjudicated by the reviewer (F.L.H.).
Statistical analysis
Odds ratios were used to evaluate the associations between APC polymorphisms and the risk of colorectal neoplasia. Pooled odds ratios and 95% confidence intervals were calculated by using Comprehensive Meta-Analysis, version 2, software (Biostat, Inc., Englewood, New Jersey) with a 2-tailed α-value of 0.05 (28) . We chose a threshold of at least 4 studies before performing a meta-analysis for subgroups.
For D1822V, we compared the risk of colorectal neoplasia in the DV heterozygote and the variant homozygote VV with the wild-type DD homozygote. In addition, we evaluated the interaction of fat intake and the D1822V polymorphisms for the risk of colorectal neoplasia by using SAS, version 9.1, software (SAS Institute, Inc., Cary, North Carolina).
For E1317Q and I1307K, we compared the frequency of variant carriers with that of wild-type carriers in the case and control groups to evaluate the associations between the 2 APC polymorphisms and the colorectal neoplasm risk. Specifically, for I1307K, the pooled frequency of variation was calculated.
Heterogeneity between the studies was measured by I 2 . If the I 2 was less than 50%, the estimated odds ratio or frequency and its confidence interval were calculated by using a fixed-effect model. Otherwise, a random-effect model was used. A sensitivity analysis was conducted by sequentially omitting individual studies. We also conducted a cumulative meta-analysis to evaluate the trend of summary odds ratios (and 95% CIs) by the year of publication. Publication biases were investigated by using a funnel plot, which was the main graphical method that was used. To supplement the funnel plot approach, the rank correlation method, as suggested by Begg and Mazumdar (29) , and the linear regression approach, as proposed by Egger et al. (30), were adopted. If a publication bias existed, the trim and fill method (31) was used to produce an adjusted pooled odds ratio and 95% confidence interval. Hardy-Weinberg equilibrium was assessed by using the χ 2 test.
RESULTS
Characteristics of the studies analyzed
Sixty-three of 474 studies were identified from the Medline, Embase, Cochrane Collaboration, and HuGE databases as primary candidates, all of which were published in English. Eleven studies were excluded because of a lack of variation or genotypic frequency for cases and controls. Eight studies were excluded because the data for estimating the odds ratio and 95% confidence interval were insufficient. Furthermore, 4 studies were duplicates. Finally, 40 studies qualified for this meta-analysis ( Table 1 ). The results of cumulative evidence showed a characterization of "strong evidence" for D1822V and "moderate evidence" for E1317Q and I1307K in this meta-analysis (Web Table 1 , available at http://aje.oxfordjournals.org/). Figure 1 shows a flowchart representing the overall search and selection process.
Q2
Of the 40 studies, 10 articles reporting 13 sets of data examined the association between the D1822V APC polymorphism and colorectal neoplasia risk and included 9,868 cases and 10,930 controls (10, 16-18, 24, 32-36) . Fifteen articles reported the association between the E1317Q APC polymorphism and colorectal neoplasia risk and included 9,069 cases and 11,341 controls (11) (12) (13) (14) (15) (16) (17) (18) (19) (37) (38) (39) (40) (41) (42) . Twentyfour articles reported the association between the I1307K APC polymorphism and colorectal neoplasia risk and the frequencies of the I1307K variation in different ethnicities (13, 14, 16, 19, 20, 37, (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) . Five articles examined both E1317Q and I1307K, 2 articles studied D1822V and E1317Q, and 1 article addressed D1822V, E1317Q, and I1307K simultaneously. For D1822V, no significant differences in genotype distribution in the population were observed, and the genotypes were under Hardy-Weinberg equilibrium (P <0.05). However, for the other 2 singlenucleotide polymorphisms (E1317Q and I1307K), the data of genotype distributions were presented only as wild-type and variant rather than as 3 separate genotypes in the included studies, and they are insufficient to properly evaluate Hardy-Weinberg equilibrium. APC I1307K. Ashkenazi Jewish patients who carried the I1307K variation had a significantly increased risk of colorectal cancer. Overall, the pooled odds ratio for the association between the I1307K polymorphism and colorectal neoplasia was 2.17 (95% CI: 1.64, 2.86) (I 2 = 0.00%), but I1307K appeared to confer no additional risk for colorectal neoplasia in non-Ashkenazi Jewish cases ( pooled OR = 1.36, 95% CI: 0.59, 3.13) (I 2 = 0.00%). Significant differences in the variation rates were found among the different racial descents. The prevalence was significantly higher among Ashkenazi Jewish cases (pooled prevalence = 11.80%, 95% CI: 10.72, 12.99) than in non-Ashkenazi Jewish cases (pooled prevalence = 2.88%, 95% CI: 1.78, 4.62) or nonJewish cases (pooled prevalence = 0.92%, 95% CI: 0.51, 1.66) (P < 0.01). The details are shown in Table 3 .
Quantitative synthesis
Sensitivity analysis
Sensitivity analyses were performed to assess the effects of each individual study on the pooled odds ratio for each analysis by sequentially removing individual studies. The results suggested that omitting each individual study had no significant influence on the pooled odds ratios for the associations between D1822V, E1317Q, and I1307K and colorectal neoplasia. However, for the pooled variation frequency of I1307K in non-Jewish patients, 1 study showed a higher carrier rate, with a total of 30 I1307K variations in 56 patients (53.60%) in the Turkish population, which increased the pooled variation frequency (1.15%) in nonJewish patients with large heterogeneity (I 2 = 94.56%). After removing this study, the pooled variation prevalence was 0.92% in non-Jewish patients and no heterogeneity was present (I 2 = 0.00%).
Cumulative meta-analysis
In the cumulative meta-analysis for the codon 1822 variant (VV vs. DD), codon 1317 variant, and codon 1307 variant, the pooled odds ratios tended toward more stability and toward significant associations as more data accumu- bias was detected only in the variant allele frequency of I1307K in Ashkenazi Jews by using Egger's linear regression approach and Begg's rank correlation method. The adjusted allele frequency of I1307K was 11.39% (95% CI: 10.11, 12.80), which was calculated by using the trim and fill method. The details are shown in Tables 2 and 3 .
Gene-fat intake interaction
In this meta-analysis, we also investigated the effect of interactions between dietary fat intake (including total fat, saturated fat, polyunsaturated fat, and monounsaturated fat) and the D1822V polymorphisms on the risk of colorectal neoplasia. In some of these studies, the data for the APC genotype at codon 1822 were considered to be wild-type or heterozygote plus variant homozygote rather than 3 separate genotypes; therefore, we can calculate the odds ratios of the D1822V polymorphisms only in the dominant model for different fat intake statuses (fat intake status: lowest level or highest level). As indicated in Table 4 , no positive interaction between fat intake and D1822V polymorphisms was found for the risk of colorectal cancer.
DISCUSSION
For the D1822V APC polymorphism, individuals with the variant homozygous VV genotype had a 13% decreased risk of colorectal neoplasia compared with those with the wildtype homozygous DD genotype. However, we set a threshold of at least 4 studies before performing a meta-analysis for subgroups, and the number of adenoma studies for the D1822V polymorphism failed to meet the standard; therefore, there were not enough data to analyze the relationships between colorectal adenoma and cancer separately.
We investigated the effect of interactions between dietary fat intake (including total fat, saturated fat, polyunsaturated fat, and monounsaturated fat) and the D1822V polymorphisms on the risk of colorectal neoplasia. However, no statistically significant positive interactions were observed in this meta-analysis between fat intake and the D1822V polymorphism. This result may be related to the data for the APC genotype at codon 1822 being given as wild-type and heterozygote plus variant homozygote rather than as 3 separate genotypes. Therefore, the given data for genotypes are not enough to evaluate the interaction of fat intake with the D1822V polymorphism on cancer risk. Another important point is that no standardized tool is available for fat intake measurement; therefore, a wide range of dietary fat components was assessed across the included studies. We removed the intermediate level and defined only 2 levels (the highest vs. the lowest) of fat according to the studies in our metaanalysis, which increased the difficulty in assessing geneenvironment interactions. Larger and more rigorous studies that provide genotype data separately are necessary to further evaluate the interactions between APC polymorphisms, fat intake, and other environmental factors and colorectal neoplasia.
For the APC E1317Q polymorphism, we observed that colorectal neoplasia risk was 41% higher in E1317Q carriers compared with noncarriers. In contrast, Rozek et al. (11) found no association between E1317Q and colorectal neoplasia, with a pooled odds ratio of 1.35. Discrepancies were detected in the conclusions of these 2 meta-analyses, but our meta-analysis study may complement and extend the results The trim and fill method provides an estimated intervention effect "adjusted" for the publication bias (based on the filled studies). Odds ratios for the association between I1307K and colorectal neoplasia and the prevalence of the I1307K polymorphism in patients are inconsistent (13, 14, 16, 19, 20, 37, (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) . In this meta-analysis, we first summarized the pooled odds ratios for the association between the variant of I1307K and colorectal neoplasia in Ashkenazi Jews, which was 2.17. This finding complements and extends the results of previous studies that showed that Ashkenazi Jews who carry the I1307K variation are at significantly increased risk for colorectal neoplasia. Significant differences in I1307K variation rates were also found in people of different ethnicities. The prevalence of I1307K in non-Ashkenazi patients ( pooled prevalence = 2.88%) and non-Jewish patients ( pooled prevalence = 0.92%) was lower compared with the prevalence in Ashkenazi patients ( pooled prevalence = 11.80%) (P < 0.01). However, there was no statistically significant difference in the prevalence of I1307K between non-Ashkenazi Jews and non-Jews (P = 0.44). Therefore, the I1307K allele of APC has a high prevalence only in the Ashkenazi Jewish population. The differences in the ethnic occurrence rates of the I1307K variation may account for the propensity of colorectal cancer in Ashkenazi Jews (49) .
Quality scores for all of the included studies ranged from 5 to 12. For E1317Q and I1307K, the data for genotype distributions were presented as wild-type and heterozygote plus variant homozygote rather than as 3 separate genotypes; therefore, the data for the genotype distributions are insufficient to properly evaluate Hardy-Weinberg equilibrium, and the quality score of the test for Hardy-Weinberg equilibrium is 0. The quality score of articles reporting on these 2 singlenucleotide polymorphisms (E1317Q and I1307K) is lower compared with that of articles reporting on D1822V. The limitation of quality assessments is that they assign lower scores to studies that do not report what was performed ( poor reporting) than to studies that clearly had inappropriate study design or analysis ( poor quality). Poor reporting is not distinguished from poor quality. The cumulative evidence on genetic associations is characterized as "strong evidence" (D1822V) and "moderate evidence" (E1317Q and I1307K), which reflects only the higher level of available evidence in this meta-analysis.
A systematic review and meta-analysis of the association between APC polymorphisms and colorectal neoplasia risk is statistically more powerful than any single study. The individual sample sizes of a single study are too small to explore the subtle associations between polymorphisms and cancer risk, but the pooled odds ratios generated from 40 studies significantly increase the statistical power. Moreover, in our meta-analysis, no obvious heterogeneity between studies was detected, and the results of the sensitivity analysis and cumulative analysis support the stability of the results. Thus, these considerations effectively support the reliability of this meta-analysis.
However, the limitations of this meta-analysis should be considered. First, of the 40 included studies, not enough studies provided genotype data separately. Second, too few studies were published to yield stable results on the interaction of fat intake with the D1822V polymorphism on colorectal neoplasia, and no studies were available on the interaction of other environmental factors with APC singlenucleotide polymorphisms on colorectal neoplasia risk. The third limitation is that all of the studies were case-control studies and therefore subject to recall bias and selection bias, which we cannot rule out.
Despite these limitations, the results of this meta-analysis provide a more complete and systematic picture of the role of these 3 APC polymorphisms in the risk of colorectal neoplasia and may provide genetic insight into possible strategies for the prevention of colorectal neoplasia. Meanwhile, our results are statistically robust and yield important conclusions.
Additional large-scale, well-designed studies with sufficient data on the genotypic and polymorphism frequency along with environmental factors and different types of neoplasia will be required to further clarify the role of these APC polymorphisms in colorectal neoplasia.
